DPP-4 and HMG-CoA reductase — Drug Target

All drugs that target DPP-4 and HMG-CoA reductase — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

DPP-4 inhibitor and HMG-CoA reductase inhibitor (statin)

Phase 3 pipeline (1)

• Gemigliptin and/or Rosuvastatin · LG Life Sciences · DPP-4 inhibitor and HMG-CoA reductase inhibitor (statin) · Diabetes and Cardiovascular
  Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol.